Loading institutional data...
Loading institutional data...
Institutional accumulation: ownership increased +0.62% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-08-05 · 15d old
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $66.6M 100.0% | $53.8M 100.0% | $46.1M 100.0% | $42.0M 100.0% | $38.0M 100.0% | $34.8M 100.0% | $27.2M 100.0% | $22.5M 100.0% | $21.9M 100.0% | $20.2M 100.0% |
| Cost of Revenue | $47.1M 70.7% | $39.3M 73.0% | $33.3M 72.3% | $28.9M 68.8% | $24.5M 64.3% | $21.7M 62.3% | $17.4M 64.0% | $14.5M 64.6% | $14.8M 67.3% | $14.3M 70.8% |
| Gross Profit | $19.5M 29.3% | $14.6M 27.0% | $12.7M 27.7% | $13.1M 31.2% | $13.6M 35.7% | $13.1M 37.7% | $9.8M 36.0% | $7.9M 35.4% | $7.2M 32.7% | $4.9M 24.4% |
| Research & Development | $3.6M 5.5% | $3.2M 5.9% | $2.8M 6.1% | $3.0M 7.1% | $4.4M 11.5% | $2.3M 6.6% | $1.9M 6.9% | $1.9M 8.4% | $1.2M 5.6% | $1.2M 6.0% |
| Selling, General & Admin | $4.8M 7.3% | $4.1M 7.6% | $4.0M 8.7% | $4.9M 11.7% | $4.1M 10.7% | $3.2M 9.2% | $2.5M 9.2% | $2.3M 10.2% | $2.5M 11.5% | $1.9M 9.3% |
| Total Operating Expenses | $8.8M 13.2% | $7.4M 13.7% | $7.0M 15.2% | $8.0M 19.1% | $9.1M 23.8% | $6.1M 17.4% | $4.8M 17.6% | $5.6M 24.7% | $4.4M 20.3% | $4.1M 20.4% |
| Operating Income | $10.7M 16.1% | $7.2M 13.3% | $5.8M 12.5% | $5.1M 12.2% | $4.5M 11.9% | $7.1M 20.3% | $5.0M 18.4% | $2.4M 10.6% | $2.7M 12.5% | $807K 4.0% |
| Interest Expense | $829K 1.2% | $558K 1.0% | $533K 1.2% | $464K 1.1% | $352K 0.9% | $236K 0.7% | $220K 0.8% | $7K 0.0% | $12K 0.1% | $37K 0.2% |
| Other Income (Expense), net | $1.4M 2.1% | -$4.5M -8.4% | $3.7M 8.0% | $571K 1.4% | $3.1M 8.1% | $836K 2.4% | $449K 1.7% | $218K 1.0% | $15K 0.1% | $321K 1.6% |
| Pretax Income | $12.1M 18.1% | $2.6M 4.9% | $9.4M 20.5% | $5.7M 13.5% | $7.6M 20.0% | $7.9M 22.7% | $5.4M 20.0% | $2.6M 11.6% | $2.8M 12.5% | $1.1M 5.6% |
| Income Tax Expense | $3.1M 4.6% | $507K 0.9% | $2.4M 5.1% | $1.1M 2.7% | $1.4M 3.8% | $1.8M 5.1% | $1.3M 4.8% | $989K 4.4% | -$2.1M -9.5% | $25K 0.1% |
| Net Income | $9.0M 13.5% | $2.1M 4.0% | $7.1M 15.3% | $4.6M 10.9% | $6.2M 16.2% | $6.1M 17.5% | $4.1M 15.3% | $1.6M 7.2% | $5.1M 23.2% | $822K 4.1% |
| Per Share | ||||||||||
| EPS (Basic) | $2.73 | $0.61 | $1.98 | $1.26 | $1.63 | $1.56 | $0.99 | $0.38 | $1.26 | $0.20 |
| EPS (Diluted) | $2.67 | $0.60 | $1.95 | $1.21 | $1.57 | $1.50 | $0.97 | $0.37 | $1.25 | $0.20 |
| Weighted Avg Shares (Basic) | 3.3M | 3.5M | 3.6M | 3.6M | 3.8M | 3.9M | 4.2M | 4.3M | 4.0M | 4.1M |
| Weighted Avg Shares (Diluted) | 3.4M | 3.6M | 3.6M | 3.8M | 3.9M | 4.1M | 4.3M | 4.3M | 4.1M | 4.2M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $4M buybacks = $4M returned.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 17%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $33000 is below the $6M due within a year — relies on refinancing or operating cash flow. Scheduled principal only (excludes interest & revolver draws). As of 2025-06-30 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~5.4% on $15M of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-08-05
Nothing notable to watch.
No material risks flagged.
Where each multiple sits in its own 14-yr range · 91th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 2.1× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 64.6 | 64.0 | 62.3 | 64.3 | 68.8 | 72.3 | 73.0 | 70.7 |
| Gross Profit | 35.4 | 36.0 | 37.7 | 35.7 | 31.2 | 27.7 | 27.0 | 29.3 |
| R&D | 8.4 | 6.9 | 6.6 | 11.5 | 7.1 | 6.1 | 5.9 | 5.5 |
| SG&A | 10.2 | 9.2 | 9.2 | 10.7 | 11.7 | 8.7 | 7.6 | 7.3 |
| Operating Income | 10.6 | 18.4 | 20.3 | 11.9 | 12.2 | 12.5 | 13.3 | 16.1 |
| Income Tax | 4.4 | 4.8 | 5.1 | 3.8 | 2.7 | 5.1 | 0.9 | 4.6 |
| Net Income | 7.2 | 15.3 | 17.5 | 16.2 | 10.9 | 15.3 | 4.0 | 13.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on PDEX: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1111 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1.05T | 51.0× | — | 16.1× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $679.0B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $620.1B | 23.4× | — | 6.6× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $435.4B | 104.3× | 31.4× | 7.1× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| UNH | $374.0B | 31.2× | 21.4× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| BDRX | $359.1B | — | — | — | — | — | — | — | — | — | 7 |
| MRK | $321.1B | 17.6× | — | 4.9× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| NVSEF | $289.9B | — | — | — | — | — | — | — | — | — | 2 |
| AZN | $250.4B | — | — | — | — | — | — | — | — | — | 1,248 |
| AMGN | $219.7B | 28.7× | 18.3× | 6.0× | 10.0% | 67.2% | 21.0% | 89.1% | 13.1% | 3.5× | 3,014 |
| TMO | $217.8B | 32.6× | 28.5× | 4.9× | 3.9% | — | 15.1% | 12.6% | 7.0% | 4.9× | 2,481 |
| ABT | $183.9B | 28.4× | 19.5× | 4.2× | 5.7% | 56.4% | 14.7% | 12.5% | 10.5% | 1.0× | 2,964 |
| GILD | $163.5B | 19.4× | 18.1× | 5.5× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| PFE | $146.7B | 19.0× | — | 2.3× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $141.1B | 39.5× | 29.3× | 5.7× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $133.2B | 47.7× | 36.6× | 13.2× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| SYK | $128.8B | 40.1× | 21.8× | 5.1× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| CVS | $126.0B | 71.3× | 12.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| VRTX | $123.1B | 31.6× | 26.9× | 10.3× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| MDT | $110.1B | 23.1× | 11.7× | 3.0× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| GLAXF | $106.9B | — | — | — | — | — | — | — | — | — | 5 |
| MCK | $102.7B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| SNYNF | $101.3B | — | — | — | — | — | — | — | — | — | 5 |
| HCA | $92.0B | 14.5× | — | 1.2× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $86.4B | 15.5× | 14.8× | 0.4× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| PDEX | $216M | 24.8× | 19.4× | 3.3× | 23.7% | 29.3% | 13.5% | 24.5% | 17.2% | 1.3× | 56 |
Peers = companies sharing PDEX's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.